Post-Secondary Success: Navigating the Transition
Summary
The first year of post-secondary can be challenging enough, but for students with learning disabilities (LD) and ADHD there can be unexpected challenges. To help with the transition, we are looking for students in Grade 11, 12, or first-year undergraduate studies to complete a game tutorial on preparing for post-secondary. The tutorial was developed by researchers at the University of Calgary and the University of Manitoba. The course contains six game chapters that contain important information about being a successful student in post-secondary (e.g. what your diagnosis means, how to access accommodations and supports, time management, budgeting, coping with stress).
We want to make this tutorial accessible to all high school students in Alberta. Before we do that, we want to know if it is effective. We are looking for your feedback on the design and content of the modules. We will use your feedback to make improvements to the tutorial.
Eligibility
Eligible ages: 16 to 22
Accepts healthy participants: Yes
Inclusion criteria:
Students who are in 1) Grade 11, 12, or first-year undergraduate studies (aged 16 and up). 2) Have a diagnosis of ADHD and/or learning disabilities. 3) Intending to apply to or currently enrolled in post-secondary education. 4) Ability to use and understand a web-based intervention in English.
Exclusion criteria:
You are not eligible to participate if you have 1) severe uncorrected impairments that may prevent application use. 2) Existing enrollment in transition programs to post-secondary education.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Stefanie Ng (Research Coordinator)
Principal investigator:
Meadow Schroeder
Clinical trial:
No
REB-ID:
REB21-1369
External links